Trevena (TRVN) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

BOSTON, Oct. 9, 2018

On May 2, 2016, the Company announced that it had "reached general agreement" with the FDA on key elements of its Phase 3 program for oliceridine (TRV130) and was "very pleased" with the outcome of its discussions with the FDA.

In fact, FDA minutes from its April 28, 2016 meeting with the Company—revealed today—show that the FDA:

• "did not agree with the proposed dosing in the Phase 3 studies";
• "did not agree with the proposed primary endpoint"; and
• "did not agree with the proposed non-inferiority (NI) margin for comparing morphine to oliceridine"

The Company's stock price has plunged more than 60%.

If you have purchased or otherwise acquired Trevena securities and have questions about your legal rights, or possess information relevant to this investigation, you are encouraged to contact attorneys John DeFelice or Jake Walker at (888) 868-2385, by email at john@blockesq.com or jake@blockesq.com, or by visiting http://shareholder.law/trevena.

Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nation's largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.